DK0401508T3 - Proteaseinhibitorer, fremgangsmåde til deres fremstilling samt lægemidler med indhold deraf - Google Patents

Proteaseinhibitorer, fremgangsmåde til deres fremstilling samt lægemidler med indhold deraf

Info

Publication number
DK0401508T3
DK0401508T3 DK90108284.2T DK90108284T DK0401508T3 DK 0401508 T3 DK0401508 T3 DK 0401508T3 DK 90108284 T DK90108284 T DK 90108284T DK 0401508 T3 DK0401508 T3 DK 0401508T3
Authority
DK
Denmark
Prior art keywords
peptide variants
preparation
trypsin inhibitor
processes
protease inhibitors
Prior art date
Application number
DK90108284.2T
Other languages
English (en)
Inventor
Hans Prof Dr Fritz
Wolfgang Dr Gebhard
Rathindra Dr Das
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of DK0401508T3 publication Critical patent/DK0401508T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
DK90108284.2T 1989-05-13 1990-05-01 Proteaseinhibitorer, fremgangsmåde til deres fremstilling samt lægemidler med indhold deraf DK0401508T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3915689 1989-05-13
DE4001244 1990-01-18

Publications (1)

Publication Number Publication Date
DK0401508T3 true DK0401508T3 (da) 1995-05-15

Family

ID=25880860

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90108284.2T DK0401508T3 (da) 1989-05-13 1990-05-01 Proteaseinhibitorer, fremgangsmåde til deres fremstilling samt lægemidler med indhold deraf

Country Status (17)

Country Link
US (1) US5407915A (da)
EP (1) EP0401508B1 (da)
JP (2) JP3126975B2 (da)
KR (1) KR0156246B1 (da)
AT (1) ATE114332T1 (da)
AU (1) AU623769B2 (da)
CA (1) CA2016627C (da)
DE (1) DE59007737D1 (da)
DK (1) DK0401508T3 (da)
ES (1) ES2066033T3 (da)
GR (1) GR3015124T3 (da)
HU (1) HU214985B (da)
IE (1) IE65710B1 (da)
IL (1) IL94349A (da)
NZ (1) NZ233635A (da)
PH (1) PH27530A (da)
PT (1) PT94016B (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134087A1 (en) * 1988-09-02 2006-06-22 Dyax Corp. ITI-D1 Kunitz domain mutants as hNE inhibitors
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US7078383B2 (en) * 1988-09-02 2006-07-18 Dyax Corp. ITI-D1 Kunitz domain mutants as HNE inhibitors
CA2055425A1 (en) * 1990-11-13 1992-05-14 Hideaki Morishita Polypeptide, dna fragment encoding the same and process for producing the same, and enzyme inhibition process, drug composition and methods of treating using the same
ES2124203T3 (es) * 1991-03-01 2004-04-16 Dyax Corp. Inhibidores de la elastasa neutrofila humana y la catepsina g humana.
CA2082226A1 (en) * 1991-11-08 1993-05-09 Hideaki Morishita Polypeptide, dna fragment encoding the same, drug composition containing the same and process for producing the same
IL104327A0 (en) * 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
JP2769083B2 (ja) * 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
JP3570558B2 (ja) * 1993-05-01 2004-09-29 持田製薬株式会社 Ｄｎａ断片およびそれを含むベクター、該ベクターによって形質転換された形質転換体、該ベクターを用いる蛋白質の産生方法
US5650394A (en) * 1993-11-04 1997-07-22 Adeza Biomedical Use of urinastatin-like compounds to prevent premature delivery
ATE529444T1 (de) 1994-01-11 2011-11-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
AU4868096A (en) * 1995-02-23 1996-09-11 Adeza Biomedical Corporation Polypeptides derived from urinastatin having calcium channel blocking activity and their use to delay premature delivery
BR9708021A (pt) * 1996-03-11 1999-07-27 Bayer Ag Proteína substancialmente purificada composição farmacêutica sequência de ácido nucleico isolada vetor de express o de protéina auto-replicante e processos para inibir a atividade de protéinas de serina tratar uma condição e preparar um medicamento de uma proteína
ES2209542T3 (es) * 1998-12-22 2004-06-16 Bayer Aktiengesellschaft Metodo para acelerar la velocidad de eliminacion mucociliar usando un inhibidor de serinproteasa de tipo kunitz.
US20070140979A1 (en) * 1998-12-22 2007-06-21 Bayer Aktiengesellschaft Method for accelerating the rate of mucociliary clearance
US6660482B1 (en) * 2000-02-28 2003-12-09 Rhode Island Hospital Inter-alpha-trypsin inhibitor as a marker for sepsis
EP1374469A1 (en) * 2001-03-27 2004-01-02 Aware, Inc. Receiver transparent q-mode
CA2488558C (en) 2002-06-07 2013-08-20 Dyax Corp. Prevention and reduction of blood loss
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK2386310T3 (da) 2002-08-28 2019-02-25 Dyax Corp Fremgangsmåder til at konservere organer og væv
DE602004031589D1 (de) * 2003-01-07 2011-04-14 Dyax Corp Kunitz-domäne-bibliothek
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2010080833A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
SI2521568T1 (sl) 2010-01-06 2019-01-31 Dyax Corp. Proteini, ki vežejo plazemski kalikrein
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp KALLIKREIN PLASMA BINDING PROTEINS
EP3110434B1 (en) 2014-02-24 2018-09-19 Takeda GmbH Uti fusion proteins
BR112016022318A2 (pt) 2014-03-27 2017-10-31 Dyax Corp método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
JP7003354B2 (ja) 2015-12-11 2022-03-04 武田薬品工業株式会社 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途
US11725043B2 (en) 2020-03-05 2023-08-15 DiaMedica USA Inc. Ulinastatin polypeptides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU560584B2 (en) * 1983-07-28 1987-04-09 Bayer Aktiengesellschaft Homologues of aprotinin
US4711848A (en) * 1984-03-14 1987-12-08 Zymogenetics, Inc. Site specific mutagenesis in alpha-1-antitrypsin
FR2599752B1 (fr) * 1986-06-10 1989-11-03 Transgene Sa Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
FR2601033B1 (fr) * 1986-07-02 1990-01-19 Transgene Sa Variants de l'alpha-antitryspine humaine glycosylee et procede pour la preparation
EP0255011A3 (en) * 1986-07-29 1988-11-23 Miles Inc. Human inter-alpha-trypsin inhibitor gene

Also Published As

Publication number Publication date
CA2016627A1 (en) 1990-11-13
IE65710B1 (en) 1995-11-15
GR3015124T3 (en) 1995-05-31
PT94016B (pt) 1997-05-28
HU214985B (hu) 1998-08-28
ATE114332T1 (de) 1994-12-15
EP0401508A3 (de) 1991-03-27
IE901713L (en) 1990-11-13
US5407915A (en) 1995-04-18
PT94016A (pt) 1991-01-08
IL94349A (en) 1998-01-04
CA2016627C (en) 2000-08-22
JPH03255099A (ja) 1991-11-13
PH27530A (en) 1993-08-18
JP2001112492A (ja) 2001-04-24
DE59007737D1 (de) 1995-01-05
AU623769B2 (en) 1992-05-21
AU5497090A (en) 1990-11-15
KR900017607A (ko) 1990-12-19
HU903010D0 (en) 1990-09-28
JP3126975B2 (ja) 2001-01-22
EP0401508B1 (de) 1994-11-23
EP0401508A2 (de) 1990-12-12
IL94349A0 (en) 1991-03-10
KR0156246B1 (ko) 1998-11-16
NZ233635A (en) 1991-12-23
ES2066033T3 (es) 1995-03-01

Similar Documents

Publication Publication Date Title
DK0401508T3 (da) Proteaseinhibitorer, fremgangsmåde til deres fremstilling samt lægemidler med indhold deraf
Johnson et al. Cathepsin L inactivates alpha 1-proteinase inhibitor by cleavage in the reactive site region.
ATE226636T1 (de) Serpin-resistenter t-pa; mutanten; gene
NO930517L (no) Benzimidazolylderivater, legemidler inneholdende disse, og fremgangsmaate for deres fremstilling
PL319782A1 (en) Inhibitors of serinic proteases and anticoagulative protecins extracted from nematodes
MX9603775A (es) Proteinas inhibidoras del dominio de kunitz, derivadas del inhibidor del precursor de la beta-proteina amiloide de alzheimer.
BR0113740A (pt) Nitrilas espiroheterocìclicas úteis como inibidores reversìveis de proteases de cisteìna
DE69635447D1 (de) Plasma-kallikrein inhibitoren vom kunitz-typ
WO1996035788A3 (en) Kunitz type protease inhibitors
WO2002076939A3 (en) Cysteine protease inhibitors
TR200002940T2 (tr) Parazitlerin sebep olduğu hastalıkların papain süperfamilyasından sistein proteazların inhibisyonu yoluyla tedavisi
ATE250574T1 (de) Neue verbindungen
DK0419099T3 (da) Proteiner med antikoagulationsegenskaber
Rowan et al. Inhibition of cysteine proteinases by a protein inhibitor from potato
NZ319474A (en) Guanidino protease inhibitors
ATE92935T1 (de) Serinproteaseinhibitoren und isolierungsverfahren dazu.
KR890004724A (ko) 신규 프로테아제 제제(製劑)
Hayashi et al. Structure–activity relationship studies of chloromethyl ketone derivatives for selective human chymase inhibitors
Takahara et al. Mouse plasma trypsin inhibitors: Inhibitory spectrum of contrapsin and alpha-1-antitrypsin
Groutas et al. Inhibitors of human neutrophil cathepsin G: structural and biochemical studies
Knäuper et al. Inactivation of human plasma C1‐inhibitor by human PMN leucocyte matrix metalloproteinases
Yusova et al. SERPINS’REACTIVE SITES LOOPS MOBILITY AND ITS FUNCTIONAL VALUE
ØDUM Trypsin-inhibitory activity of ovalbumin preparations is due to ovomucoid
Ascenzi et al. Binding of the Bovine Basic Pancreatic Trypsin Inhibitor (Kunitz) to the 33,000 M r and 54,000 M r Species of Human Urokinase: Thermodynamic Study
Ecke et al. Alternative targeting of a serpin-type inhibitor by glycosaminoglycans (GAGs): Heparin binding of protein C inhibitor (pci) prevents its interaction with tissue kallikrein (tk)